Edwards Lifesciences (EW) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Edwards Lifesciences (EW) right now is TAVR leadership and label expansion: TAVR remains the core franchise, generating about $4.49 billion in 2025, up roughly 9.3% year over year, and Edwards held an estimated low-70s percent share of the U.S. Total revenue (FY2025) is ~$6.07 billion, up ~11.5%. If that keeps playing out, the setup is favourable; the risk to it is edwards faces several headwinds at once. No one can predict where EW trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Edwards Lifesciences (EW) higher?
1. TAVR leadership and label expansion.
TAVR remains the core franchise, generating about $4.49 billion in 2025, up roughly 9.3% year over year, and Edwards held an estimated low-70s percent share of the U.S. market. The EARLY TAVR trial supports treating asymptomatic severe aortic stenosis patients, and an expanded FDA indication could enlarge the eligible patient pool. Boston Scientific's 2025 exit from TAVR removed one competitor, leaving Medtronic and Abbott as the main rivals.
2. TMTT as the growth engine.
Transcatheter mitral and tricuspid therapies grew about 56% in 2025 to roughly $551 million, driven by the PASCAL repair system, EVOQUE tricuspid valve, and SAPIEN M3 mitral valve. Management guided 2026 TMTT revenue of about $740 to $780 million, implying 35% to 45% growth. This franchise is the clearest path to extending Edwards' structural-heart leadership beyond aortic valves.
3. High margins and strong cash generation.
Edwards runs gross margins near 78%, reflecting the value of differentiated implantable devices and entrenched clinical adoption. That profitability funds heavy R&D and a steady acquisition program. The company returns cash through buybacks, completing a roughly $500 million repurchase in early 2026 with about $1.5 billion remaining under authorization rather than paying a dividend.
4. Pipeline and acquisitions.
Edwards spent about $1.2 billion acquiring JenaValve, which targets aortic regurgitation, and Endotronix, which brings heart-failure monitoring into its ecosystem. These deals expand the addressable market beyond aortic stenosis. Combined with internal programs, they aim to sustain durable growth, though new indications and devices must clear regulatory and reimbursement hurdles before they contribute meaningfully.
What could weigh on EW?
Edwards faces several headwinds at once. TAVR growth has decelerated as the aortic-stenosis market matures, and competition from Medtronic's Evolut platform and Abbott's Navitor could erode share even after Boston Scientific's exit. Much of the business depends on favorable reimbursement and FDA decisions, so a delayed or narrowed label expansion (such as for asymptomatic patients) would hurt the growth story. The stock typically trades at a premium multiple, often well above the broad market, which leaves little margin for error if results disappoint. Finally, integrating acquisitions like JenaValve and Endotronix carries execution risk and may pressure near-term margins before the pipeline pays off.
How to think about a EW forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the EW guide and whether EW is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the EW outlook
The bottom line: what is driving Edwards Lifesciences (EW) is TAVR leadership and label expansion, with total revenue (fy2025) at ~$6.07 billion, up ~11.5%. If that keeps playing out the setup is favourable; the risk is edwards faces several headwinds at once. No one can predict the price, so treat any EW forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around EW with Walnut
Use Edwards Lifesciences as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Edwards Lifesciences (EW)?
+
No one can reliably predict where EW will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Edwards Lifesciences higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive EW higher?
+
The main growth drivers are TAVR leadership and label expansion; TMTT as the growth engine; High margins and strong cash generation. Whether they play out is the real question, not a guaranteed path.
What are the risks to EW?
+
Edwards faces several headwinds at once. TAVR growth has decelerated as the aortic-stenosis market matures, and competition from Medtronic's Evolut platform and Abbott's Navitor could erode share even after Boston Scientific's exit. Much of the business depends on favorable reimbursement and FDA decisions, so a delayed or narrowed label expansion (such as for asymptomatic patients) would hurt the growth story. The stock typically trades at a premium multiple, often well above the broad market, which leaves little margin for error if results disappoint. Finally, integrating acquisitions like JenaValve and Endotronix carries execution risk and may pressure near-term margins before the pipeline pays off.
Will EW stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Edwards Lifesciences's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is EW a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the EW "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.